Clinical Trial Update: Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001) [Phase 3]

View source ↗

Summary

This update documents a Phase 3 trial (RT1001) evaluating prophylactic cranial irradiation in NSCLC patients who respond to EGFR inhibitors erlotinib or gefitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN